The important question around compounded semaglutide is practical: what is actually known, what remains uncertain, and what safeguards a licensed clinician and pharmacy process add before anyone treats it as an option.
A woman I saw virtually last October, a school administrator in her late forties from outside Raleigh, told me she’d spent four months calling around to pharmacies and insurance lines before she even heard the word “compounded.” Her employer plan covered Ozempic for diabetes but not Wegovy for weight management, and the cash price she was quoted at a Walgreens near her house was $1,347. She’d been reading about semaglutide for over a year. She knew more about the STEP trials than some residents I’ve supervised. What she didn’t know was how to think about the difference between a branded product and a compounded one, or whether that difference should worry her.
That conversation, some version of it, happens in my inbox or on a video visit almost daily. So this piece is an attempt to lay out what compounded semaglutide actually is, what the clinical data says, and where the real questions are, without pretending the answers are simpler than they are.
The Molecule vs. the Product
Semaglutide is a GLP-1 receptor agonist. Novo Nordisk developed it, brought it to market as Ozempic in 2017 for type 2 diabetes, then as Wegovy in 2021 for chronic weight management. The molecule itself is well studied. What gets confusing is the distinction between the molecule and the product on the shelf.
Brand-name Ozempic and Wegovy are FDA-approved finished products. They go through registrational trials, carry an FDA label, and are manufactured at industrial scale. Compounded semaglutide contains the same active pharmaceutical ingredient, but it’s prepared by a state-licensed or 503A compounding pharmacy for an individual patient under a clinician’s prescription. It is not FDA-approved as a finished product.
That’s an important distinction, and it’s worth sitting with for a second. Compounding isn’t some fringe workaround. It’s a well-established pathway governed by section 503A of the Federal Food, Drug, and Cosmetic Act and state pharmacy regulations. Pharmacies compound medications across dozens of drug classes every day, from hormone therapies to pediatric suspensions. But compounded preparations haven’t gone through the same registrational trial process as the brand. So when we cite STEP trial data, we’re citing evidence built on the branded product. It informs our understanding of compounded semaglutide. It doesn’t directly extend to it.
The honest version: if the active ingredient is the same, you’d expect the pharmacological effect to track. But “expect” and “proven through a Phase 3 program” are different categories, and a responsible clinician names that gap rather than waving it away.
See also: The Future of Solar Energy Technologies
What the Trials Actually Show
The STEP program is the backbone of the clinical evidence for semaglutide in weight management. Here’s what the numbers look like.
STEP-1 randomized 1,961 adults with overweight or obesity (no diabetes) to weekly semaglutide 2.4 mg or placebo for 68 weeks, with a lifestyle intervention in both arms. The semaglutide group lost approximately 14.9% of body weight from baseline, compared with 2.4% in the placebo group (Wilding et al., New England Journal of Medicine, 2021). That’s a striking result, though individual responders ranged widely, from around 5% to north of 20%.
STEP-3 layered intensive behavioral therapy on top and found a directionally similar, slightly larger effect. STEP-5 followed patients for 104 weeks and showed sustained weight reduction in the active arm. STEP-4 is the one that sobers people up a bit: participants who were switched to placebo after an initial treatment period showed significant weight regain, suggesting that for many patients, the metabolic benefit depends on staying on therapy.
On the diabetes side, the SUSTAIN program established the glycemic and cardiovascular signal at lower doses (0.5 mg, 1.0 mg, with 2.0 mg added later in SUSTAIN FORTE). SUSTAIN-6 (Marso SP et al.) reported a reduction in the composite of major adverse cardiovascular events in a high-risk diabetes population.
The overall picture: semaglutide produces clinically meaningful effects on weight and blood sugar, with a side-effect profile that’s well characterized and heaviest in the early weeks of dose escalation.
How Dosing Works (and Where Flexibility Matters)
The standard titration from the STEP trials and the Wegovy label is a five-step climb: 0.25 mg weekly for four weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg as maintenance. Full escalation takes roughly sixteen to seventeen weeks.
Most compounded programs follow the same schedule and milligram increments, though the concentration of the preparation and the volume you draw into the syringe will vary by pharmacy. This trips people up. The dose that matters is the milligram dose, not how many units you draw. If you’re switching between programs or pharmacies, confirm the milligrams at each step.
Here’s where clinical judgment comes in. The schedule isn’t a railway track. A patient who’s miserable with nausea at 0.5 mg can sit at that dose for an extra four weeks before stepping up. A patient doing well at 1.7 mg, meeting their goals, tolerating it fine, can choose to stay there rather than push to 2.4 mg. I’ve had patients plateau at 1.0 mg and do beautifully for months before we revisited escalation. The protocol is a scaffold, not a mandate.
Storage is straightforward but matters: refrigerate at 36 to 46 degrees Fahrenheit, with limited room-temperature time acceptable for transport. Rotate injection sites between abdomen, thigh, and upper arm to reduce local irritation. These aren’t glamorous details, but they’re the ones that affect your Tuesday morning.
Side Effects: The Boring Truth
GI symptoms dominate. Nausea, diarrhea, constipation, vomiting, abdominal discomfort. Across STEP and SUSTAIN trials, and in real-world cohorts, these are the most common complaints. Most are mild to moderate, concentrated in the first eight to twelve weeks, and resolve with continued therapy or a temporary dose adjustment.
Less common but more serious: gallbladder events (especially in patients losing weight rapidly), acute pancreatitis (rare, but if you develop severe abdominal pain radiating to your back, that’s an urgent call, not a “wait and see”), and a theoretical thyroid C-cell tumor signal from rodent data that hasn’t been replicated in humans. The Wegovy and Ozempic labels carry a boxed warning about the rodent finding and a contraindication for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2).
Hypoglycemia on semaglutide alone, in a non-diabetic patient, is uncommon because the insulin-stimulating effect is glucose-dependent. Think of it like a thermostat: it turns on when blood sugar is high and quiets down when it’s not. The risk goes up when semaglutide is combined with insulin or sulfonylureas in diabetic patients, and in that setting, the other medications usually need dose adjustment.
My opinion: the side-effect conversation is the single most reliable marker of program quality. A good program walks you through what to expect during titration, names the warning signs for the uncommon stuff, and has a clear protocol for when to pause or reduce. A program that glosses over this part is one I’d be skeptical of.
The Cost Question
Brand-name Wegovy and Ozempic list above $1,300 per month in the US. Cash-pay rates at most retail pharmacies land somewhere between $1,000 and $1,400. Insurance coverage for weight management is inconsistent (generous description). The diabetes indication has better coverage, but it varies by plan, by employer, by year.
Compounded semaglutide through compliant telehealth programs costs substantially less. HealthRX, which operates under LegitScript certification and is available in 44 US states, prices its program at $179.99 to $279.99 per month depending on dose. That’s not a typo, and the gap isn’t magic. Brand-name products carry the full cost burden of large-scale manufacturing, regulatory submissions, post-marketing surveillance, and the commercial margin Novo Nordisk needs to fund the next generation of drug development. Compounded preparations are produced at a different scale, through a different regulatory pathway, with a different cost structure.
If you plan to use HSA or FSA funds, confirm the program’s invoicing format before you enroll. Some plans accept it without issue; others require specific documentation.
For a patient-facing reference that covers mechanism, dosing, and the safety conversation in readable language, https://healthrx.com/guides/compounded-semaglutide is a solid starting point. It won’t replace a real clinical conversation, but it’s the kind of background reading that makes that conversation more productive.
When to Call Your Clinician (Not Google)
Some situations need a phone call or a message to your prescribing program, not a Reddit thread.
Persistent severe abdominal pain, particularly with radiation to the back or fever: call now. Inability to keep down fluids for more than 24 hours, signs of dehydration, persistent vomiting: call now. New right upper quadrant pain after meals or jaundice (possible gallbladder): get evaluated. New or worsening reflux that doesn’t respond to meal-timing adjustments: raise it at your next visit. Mood changes, including new depressive symptoms: surface it, don’t minimize it.
Pregnancy, planned pregnancy, or breastfeeding: have the conversation before your next dose. History of medullary thyroid carcinoma or MEN2 should have been flagged at intake; if it wasn’t, that’s urgent.
Patients on insulin, sulfonylureas, warfarin, or other medications with narrow therapeutic windows should be especially communicative with their prescribing clinician. Semaglutide slows gastric emptying, and that can change the absorption profile of other medications you’re taking.
Frequently Asked Questions
Is compounded semaglutide the same drug as Ozempic and Wegovy?
The active ingredient, semaglutide, is the same. The finished product, regulatory category, and manufacturing pathway are different. Ozempic and Wegovy are FDA-approved finished products from Novo Nordisk. Compounded semaglutide is prepared by a licensed compounding pharmacy for an individual patient under a clinician’s prescription and is not FDA-approved as a finished product.
How long does treatment typically last?
STEP-1 captured 68 weeks, STEP-5 extended to 104 weeks, and clinical experience now runs beyond two years. Duration is individualized based on goals, response, and tolerability.
Is the weight reduction sustained after stopping?
STEP-4 showed significant regain in the group switched to placebo after a lead-in period. For many patients, maintaining the metabolic benefit requires continued therapy. Long-term outcomes after discontinuation depend on the lifestyle changes consolidated during treatment.
Do I need labs to start?
A careful program documents baseline labs, which may include a metabolic panel, lipid panel, A1c, and in some patients a thyroid panel. The specific set depends on your clinical picture.
Is semaglutide right for everyone?
No. Pregnancy, breastfeeding, personal or family history of medullary thyroid carcinoma or MEN2, and certain GI conditions are contraindications or relative contraindications. A thorough intake conversation should surface these before therapy begins.
What’s the difference between 503A and 503B pharmacies?
503A pharmacies compound individual prescriptions for individual patients. 503B outsourcing facilities can produce compounded preparations in larger quantities without patient-specific prescriptions and are subject to FDA oversight under a different framework. Both are legitimate pathways; the regulatory structure differs.
Can I switch from branded semaglutide to compounded (or vice versa)?
Yes, as long as the milligram dose is confirmed and your prescribing clinician is involved in the transition. The key is continuity of the milligram dose, not matching the volume of solution.
References: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384:989-1002 (STEP-1). Wadden TA et al. STEP-3. Rubino DM et al. STEP-4. Garvey WT et al. STEP-5. Davies M et al. STEP-2. SUSTAIN-6 (Marso SP et al.). Wegovy and Ozempic prescribing information (Novo Nordisk).
Important Notice
Not FDA-approved. Compounded semaglutide is prepared by licensed compounding pharmacies for individual patients based on a prescriber’s clinical judgment. This article is educational and does not constitute medical advice. Individual results vary.
